{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-033289","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-07-15T12:30:36+00:00","discovered_at":"2026-07-15T12:35:00.572442+00:00","generated_at":"2026-07-15T12:35:05.893007+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kairos Pharma reports zero Grade 3+ toxicities from ENV-105 in Phase 1 NSCLC trial","bullets":["Zero Grade 3+ toxicities from ENV-105 in 13 patients with advanced EGFR-mutated NSCLC.","ENV-105 (carotuximab) combined with osimertinib (Tagrisso) shows clean safety profile.","Targets $10B drug resistance market; no FDA-approved agent to reverse osimertinib resistance.","Phase 1 trial ongoing; safety data supports continued development toward efficacy readout."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-033289","json":"https://secwatch.observer/filing/0001493152-26-033289.json","markdown":"https://secwatch.observer/filing/0001493152-26-033289.md","text":"https://secwatch.observer/filing/0001493152-26-033289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/0001493152-26-033289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226033289/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-15T12:35:05.893007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}